HTB South


Prevalence of transmitted drug resistance globally: highest in Australia, US and some European countries but between-country differences in all regions

Higher rates of K65R in non-B subtype in large UK cohort and implications of tenofovir resistance in resource-limited settings

Drug resistance and integrase inhibitors: potential impact of HIV subtype

Drug resistance in children after PMTCT and early treatment

Genotyping using dried blood spots in rural South African setting

NNRTI resistance found in 12% of people stopping treatment with undetectable viral load: implications for stock-outs

Persistence of transmitted drug resistance mutations suggests source partners may be treatment-naive

Dolutegravir update: treatment-naive and -experienced patients and drug resistance

Higher intracellular concentrations with tenofovir alafenamide (TAF) overcomes K65R and other key NRTI resistance in vitro

Tentative phenotypic cut offs for dolutegravir: guidance for use with integrase resistance

S/GSK744 and long-acting formulation indicate broadly similar resistance profile to dolutegravir

ddI resistance in South African children failing an abacavir or d4T based first-line regimen

US label changes for rilpivirine and Eviplera follows EU caution on high baseline viral load: new summary on drug resistance

In vitro resistance profile for BMS 986001

Recombination dynamics in case of MDR sub-type D following superinfection with wild-type sub-type B

Defective viral reservoir populations is common in patients on long-term suppressed ART

First case report of transmission with five-class resistance

New data on the Berlin patient: interpret with caution

Free online resource for treatment decisions without access to genotype resistance tests

No significant difference in virological failure found between once-yearly versus twice-yearly viral load monitoring in Thai study

Model predicts rate of transmitted drug resistant virus in resource-limited settings

Rate of accumulation of TAMS slow in patients continuing on failing AZT or d4T containing regimens